On the Archetypal Nature of Bad Trips and Freakouts A Review of : "Confrontation With the Unconscious: Jungian Depth Psychology and Psychedelic Experience" by Scott J. Hill Danny Wedding, Peter H Addy PsycCRITIQUES, June 16, 2014, Vol. 59, No. 24, Article 4 © 2014 American Psychological Association In 1967 Scott J. Hill had a terrifying and traumatic experience after taking LSD, experiencing “the depths of madness and hell” (p. xiii). He became suicidal and dissociated, and he wondered whether he had gone insane. Over the next four decades, he struggled with the terror he felt during that experience; he could not come to terms with [...]
Lire la suiteBIBLIOGRAPHIE : Substances Psychédéliques et Santé Mentale Dr Christian SUEUR, GRECC, septembre 2020. Psychédéliques : neurobiologie et psychopharmacologie : 1 - 3 Psychédéliques et réactions indésirables : 4 - 5 Psychédéliques et psychopathologie : 6 - 7 Psychédéliques et « psychoses induites » : 8 - 9 Psychédéliques et “Flash Backs” (Hallucinogen-Persisting Perception Disorders) : 10 - 11 Psychédéliques et « Bad trip » : 11 Psychédéliques et Réduction des risques : 12
Lire la suiteWhat to Know About Peyote Use By Buddy T Medically reviewed by Steven Gans, MD VeryWell Mind.com, Updated on February 14, 2020 https://www.verywellmind.com/how-long-does-peyote-stay-in-your-system-80310 kedsirin jaidee / Getty Images Peyote (Lophophora williamsii or Lophophora diffusa) is a small, spineless cactus that is found in the southwest United States, northern Mexico and Peru. The plant has been used for about six thousand years by native tribes for religious and healing purposes. Peyote's principal active ingredient is mescaline, a psychedelic compound that can also be man-made through chemical synthesis.1 The peyote buttons, protrusions found on the tops of the cactus plants, are usually dried and then chewed or [...]
Lire la suiteThe “Endless Trip” among the NPS Users : Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review Laura Orsolini, Gabriele Duccio Papanti, Domenico De Berardis, Amira Guirguis, John Martin Corkery and Fabrizio Schifano Frontiers in Psychiatry, 2017, Vol. 8, article 240 doi: 10.3389/fpsyt.2017.00240 Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, cannabis, methylenedioxy-methamphetamine (MDMA), psilocybin, mescaline, and psychostimulants. The recent emergence of novel psychoactive substances (NPS) posed a critical concern regarding the new onset of psychiatric symptoms/syndromes, including cases [...]
Lire la suiteHallucinogen persisting perception disorder after psilocybin consumption : a case study Marie-Laure Espiard, Laurent Lecardeur, Pascale Abadie, Isabelle Halbecq, Sonia Dolfuss European Psychiatry, 2005, 20, (5-6), 458-60 DOI: 10.1016/j.eurpsy.2005.04.008 Abstract The recurrence of flashbacks without acute or chronic hallucinogen consumption has been recognized in the DSM IV criteria as the hallucinogen persisting perception disorder (HPPD). Perceptual disturbances may last for 5 years or more and represent a real psychosocial distress. We reported here a case of a 18 year-old young man presenting HPPD after a mixed intoxication with psylocibin and cannabis. This report shows symptomatic recurrences persisting more than 8 months. Various differential diagnoses were [...]
Lire la suiteSurvey study of challenging experiences after ingesting psilocybin mushrooms : Acute and enduring positive and negative consequences Theresa M. Carbonaro, Matthew P. Bradstreet, Frederick S. Barrett, Katherine A. MacLean, Robert Jesse, Matthew W. Johnson and Roland R. Griffiths Journal of Psychopharmacology, 2016, 1 –11 DOI: 10.1177/0269881116662634 Abstract Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst “bad trip”) after consuming psilocybin mushrooms. Thirty-nine percent rated it among the top five most challenging [...]
Lire la suiteLysergic acid diethylamide : a drug of ‘use’ ? Saibal Das, Preeti Barnwal, Anand Ramasamy, Sumalya Sen and Somnath Mondal Therapeutic Advances in Psychopharmacology, 2016, Vol. 6, (3), 214–228 DOI: 10.1177/2045125316640440 Abstract : Lysergic acid diethylamide (LSD), described as a classical hallucinogen, began its journey from the middle of the last century following an accidental discovery. Since then, it was used as a popular and notorious substance of abuse in various parts of the world. Its beneficial role as an adjunct to psychotherapy was much unknown, until some ‘benevolent’ experiments were carried out over time to explore some of its potential uses. But, many [...]
Lire la suiteInside bad trips : Exploring extra-pharmacological factors Genis ONA Journal of Psychedelic Studies, 2018, 2, (1), pp. 53–60 DOI: 10.1556/2054.2018.001 Objective : This study aimed to clarify the influence of extra-pharmacological factors in the etiology of bad trips, a common adverse reaction related to the consumption of psychedelic drugs. Methods : A descriptive approach was adopted. The information was collected using a web-based survey. The survey respondents volunteered to participate based on the condition that they had suffered a bad trip in the past. Results : This report reveals some variables that are commonly related to this adverse reaction (i.e., the recreational consumption of drugs, the [...]
Lire la suiteLSD : le retour de l’enfant terrible par Didier ACIER pour laviedesidees.fr, https://laviedesidees.fr/LSD-le-retour-de-l-enfant-terrible.html 6 mars 2015 Indissociable du mouvement hippie, l’usage récréatif de LSD-25 a donné lieu à l’interdiction précoce de ce médicament. Le potentiel psychothérapeutique de l’acide lysergique diéthylamide est pourtant bien établi, notamment en matière de soins palliatifs, et l’on peut souhaiter que l’exploration scientifique et médicale de ce produit se développe à l’avenir. Genèse d’un médicament Printemps 1943 en Suisse, à Bâle. Albert Hoffmann, chimiste de son état, synthétise pour la compagnie Sandoz, des alcaloïdes, à partir de l’ergot de seigle. Sa recherche vise à développer de nouveaux médicaments. Alors qu’il travaille sur l’acide [...]
Lire la suite